Synthesis and characterization of DFO-ZEGFR:03115
Conjugation of DFO to ZEGFR:03115 In a 1.5 mL low-protein binding centrifuge tube, a 2.3 mg/mL solution of ZEGFR:03115-Cys in 0.2 M sodium acetate (175 μL, ca 59.8 nmol) was diluted with PBS (150 μL) and 0.1 M EDTA (40 μL). A freshly prepared 0.05 mg/μL TCEP-HCl in PBS solution (8.6 μL, 1.50 μmol) was added, and the mixture was incubated in a thermomixer at 85°C for 5 min (850 rpm) followed by 25 min at room temperature. A 0.024mg/mL solution of DFO-maleimide in DMSO was then added (70.8 μL, 1.7 mg, 2.39 μmol) and the solution was incubated in a thermomixer at 37 °C for 2 h (850 rpm). The product was purified by semipreparative reverse phase high performance liquid chromatography (RP-HPLC) using Gradient 1. The fractions containing the product were lyophilized and quantified by measuring the UV absorbance at 280 nm and using the coefficient 1 Abs280 = 0.405 mg/mL (278 μg, 49.0% yield). Analytical RP-HPLC was performed using Gradient 2: Rt = 10:51 min:sec Radiosynthesis Fig. 1 . HPLC chromatograms of (A) DFO-ZEGFR:03115 reaction mixture and (B) purified DFO-ZEGFR:03115 analyzed using Gradient 2. The absorbance was recorded at the wavelength of 230 nm. The excess of TCEP and DFO-maleimide elutes at the solvent front. 89 Zr solution) were performed in preference of a large single reaction. In short, the required amount of 89 Zr-oxalic acid solution (ca 54-72 MBq) was transferred into a 1.5 mL centrifuge tube followed by a freshly prepared 2.0 M Na2CO3 solution in a 89 Zr to Na2CO3 ratio of 1:0.45 (v/v). The mixture was incubated for 3 min at room temperature. Successively, 0.5 M HEPES (pH 7.1) was added to the solution in a HEPES to 89 Zr solution ratio of 2.5:1 (v/v) to have a final pH of 7. The DFO-conjugate in HEPES pH 7.1 (1 mg/mL, 11.00-12.00 µL) was added to aliquots of the buffered 89 Zr solution (18 MBq). The mixture was incubated for 1 h at room temperature. The radiolabeling efficiency was determined by ITLC using ITLC-SG strips and 0.1 M citrate buffer (pH 5.0) as eluent. The radioconjugate appears at the origin (Rf = 0.0-0.1) while the 89 Zr 4+ which is not bound to the affibody molecule is running with the solvent front (Rf = 0.9-1.0). Radiometal incorporation ≥ 95%. Final specific activity 1.5-1.6 MBq/µg. Radiosynthesis Fig. 2 . Representative radio-ITLC of the crude radiolabeling mixture of 89 Zr-DFO-ZEGFR:03115. Radio-ITLC was run on silica-impregnated ITLC strips using 0.1 M citrate buffer (pH 5.0) as the mobile phase.
In vitro serum stability of 89 Zr-DFO-ZEGFR:03115 The stability of 89 Zr-DFO-ZEGFR:03115 with respect to loss of radioactivity from the radiolabeled affibody molecule, was assessed by incubating the radioconjugate (ca 1 MBq) in mouse serum (500 µL) in a Thermomixer at 37°C for 1 h (300 rpm). Samples were taken at 1 and 3 h and analyzed by ITLC-SG using 0.1 M citrate buffer (pH 5.0) as eluent. 89 Zr-oxalate solution (ca 1 MBq) incubated in mouse serum (500 µL) was processed in the same way and used as control. The experiments were performed in triplicate. The data are expressed as the average of n = 3 measurements ± SD (ITLC image). RCPserum = 94.6±0.5%
Solvent front: 
Synthesis and characterization of NOTA-ZEGFR:03115
Conjugation of NOTA to ZEGFR:03115 In a 1.5 mL low protein binding centrifuge tube, a 2.3 mg/mL solution of ZEGFR:03115-Cys in 0.2 M sodium acetate (300 μL, ca 102 nmol) was diluted with PBS (250 μL) and 0.1 M EDTA (60 μL). A freshly prepared 0.05 mg/μL TCEP-HCl in PBS solution (14.6 μL, 2.55 μmol) was added, and the mixture was incubated in a thermomixer at 85°C for 5 min (850 rpm) followed by 25 min at room temperature. Maleimidoethylmonoamide NOTA (MMA-NOTA) was then added (2.2 mg, 4.0 μmol) to the solution which was incubated in a thermomixer at 37 °C for 2 h (850 rpm). The product was purified by semipreparative reverse phase high performance liquid chromatography (Gradient 1). The fractions containing the product were lyophilized and quantified by measuring the UV absorbance at 280 nm on a Nanodrop 2000 using the coefficient 1 Abs280 = 0.405 mg/mL (387.6 μg, 53.2% yield). Analytical RP-HPLC was performed using Gradient 2: Rt = 10:51 min:sec To a 1.5 mL low protein binding plastic tube containing the lyophilized NOTA-ZEGFR:03115 (15 nmol), 2 mM AlCl3 (6.0 μL, 12 nmol) in 0.5 M sodium acetate buffer at pH 4, aqueous non-purified 18 F-fluoride (150-200 MBq), followed by an equal volume of ethanol, were added. The mixture was heated at 100°C for 15 min. After cooling to ambient temperature, the solution was diluted with 0.1% aq TFA (70 μL) and purified by RP-HPLC using Gradient 3: Rt = 8:30 (min:sec). The collected fraction containing the product was diluted with 0.1% aq TFA (3 mL) and loaded on an Oasis HLB-SPE cartridge (1 mL, 30 mg). The trapped radioactivity was washed with 0.1% aq TFA (4 mL) and then eluted with 60% ethanol/water (v/v, ca 120 μL). The product was quantified by measuring the UV absorbance at 280 nm on a Nanodrop 2000 using the coefficient 1 Abs280 = 0.405 mg/mL. Synthesis time (from the beginning of the reaction) = ca. 40 min. Specific activity (decay corrected to end of reactionpurification) = 0.57-1.09 MBq/µg (4.15-7.84 MBq/nmol). Protein recovery = 10.56−34.5%; RCY (decay corrected) = 10.7−38.0% Determination of the distribution coefficient (LogD) at pH 7.4 of 18 F-AlF-NOTA-ZEGFR:03115 18 F-AlF-NODA-ZEGFR:03115 (ca 0.05MBq) was added to 0.5 mL of PBS (pH 7.4). An equal volume of n-octanol was added and the mixture was vortexed for 10 min followed by centrifugation at 100 × g for 10 min. The experiments were performed in triplicate. Three 100 µl samples were taken from each layer and the amount of activity was measured in a 2480 WIZARD 2 Automatic Gamma Counter (Perkin Elmer, UK) as counts per minutes (cpm). The distribution coefficient at pH 7.4 (logD7.4) was expressed as the mean ± standard deviation (SD) and calculated using the formula: LogD = log[(countsoctanol)/(countsPBS)] Result: LogD7.4 = -1.13 ± 0.1
In vitro serum stability of 18 F-AlF-NOTA-ZEGFR:03115
The stability of 18 F-AlF-NOTA-ZEGFR:03115 with respect to change in RCP and loss of radioactivity from the affibody molecule, was assessed by incubating the purified radioconjugate (ca 4.5 MBq) in mouse serum (500μL, Sigma-Aldrich, UK) in a thermomixer at 37 °C for 1 h (850 rpm). Ethanol (300 μL) was added and the suspension was centrifuged at 16000 × g for 2 min at 22 °C. The supernatant was separated from the pellet and DMF (300 μL) was added to the supernatant. The resulting suspension was centrifuged at 16000 × g for 2 min at 22 °C. The supernatant was separated from the pellet, acidified with 0.1% aq TFA (300 μL), filtered through a 0.2 μ Iso-Disc PVDF syringe filter, and analyzed by RP-HPLC using Gradient 2. The radioactivity associated with the pelleted proteins was measured in a dose calibrator. Aqueous non-purified 18 F-Fluoride solution (ca. 4 MBq) incubated in mouse serum (500 μL) was processed in the same way and used as control to confirm the Rt of free 18 F-Fluoride. The quantity (%) of intact radioconjugate was calculated as the ratio between the integral of the peak corresponding to the radioligand and the integral of the whole run. The data are expressed as the average of n = 3 measurements ±SD. RCPserum = 95.82 ± 0.67%. A residual activity associated with the pelleted protein (30.49 ± 2.1%) shows some nonspecific affinity of the radioconjugate toward the serum proteins. 
